Compass Therapeutics

CMPX · Nasdaq · United States

Share price · CMPX

$0.61-1.78 (-74.44%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.8M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CMPX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-14.5%
  2. 5 Oct 2026+12.1%
  3. 1 Oct 2026-13.4%
  4. 22 Sep 2026-31.9%
  5. 12 Aug 2026+7.7%
  6. 7 Aug 2026+8.0%
  7. 5 Aug 2026-4.5%
  8. 27 Apr 2026-64.4%
  9. 20 Apr 2026-9.8%
  10. 17 Apr 2026-8.1%

Share of unusual movement by asset

For each asset, the share of CMPX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
tovecimig
events and moves
934%
CTX-8371
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—53%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2/3
DLL4 x VEGF-AMultispecific antibody
Biliary Tract Cancer
Phase 1
PD-1 and PD-L1Multispecific antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
tovecimigPhase 2/3Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Est. primary completion 2027-08-31 · NCT05506943 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 April 2026Topline resulttovecimigCOMPANION-002 secondary endpoints of tovecimig: PFS improved, overall survival not improved
Compass Therapeutics · Source ↗
1 April 2025Topline resulttovecimigCOMPANION-002 Phase 2/3 primary endpoint met

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$22M$41M+ $122M short-term inv.$27M-$16M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$20M$35M+ $144M short-term inv.$25M-$15M operating cash flowreport ↗
2026-Q1—$13M$55M+ $140M short-term inv.$18M-$17M operating cash flowreport ↗
2025-Q3$0$13M$46M+ $174M short-term inv.$14M-$11M operating cash flowreport ↗
2025-Q2$0$16M$23M+ $78M short-term inv.$20M-$12M operating cash flowreport ↗
2025-Q1—$13M$41M+ $72M short-term inv.$17M-$13M operating cash flowreport ↗
2024-Q3$0$8.6M$37M+ $99M short-term inv.$10M-$11M operating cash flowreport ↗
2024-Q2$0.8M$11M$19M+ $127M short-term inv.$13M-$11M operating cash flowreport ↗
2024-Q1—$9.5M$24M+ $133M short-term inv.$11M-$14M operating cash flowreport ↗
2023-Q3$0$8.8M$30M+ $133M short-term inv.$10.0M-$5.9M operating cash flowreport ↗
2023-Q2$0$10M$19M+ $149M short-term inv.$11M-$10M operating cash flowreport ↗
2023-Q1—$6.6M$27M+ $148M short-term inv.$7.8M-$12M operating cash flowreport ↗
2022-Q3—$9.8M$16M+ $104M short-term inv.$12M-$11M operating cash flowreport ↗
2022-Q2—$5.9M$26M+ $106M short-term inv.$8.5M-$4.6M operating cash flowreport ↗
2022-Q1—$4.4M$136M$7.2M-$7.9M operating cash flowreport ↗
2021-Q3—$3.1M$26M$6.0M-$3.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$56M$31M+ $178M short-term inv.$17M-$49M operating cash flowreport ↗

For FY2025, Compass Therapeutics reported revenue of $0M, a 100.0% YoY decrease from $0.85M, and R&D spend of $55.97M, up 32.2% YoY. The company ended the period with cash and equivalents of $30.64M and reported a net loss of $66.49M (quarterly net burn of $66.49M).

Compass is a clinical-stage oncology biopharmaceutical company advancing four product candidates. Its lead bispecific antibody tovecimig (DLL4 x VEGF-A) met the primary endpoint in a randomized Phase 2/3 biliary tract cancer trial, with an ORR of 17.1% versus 5.3% for paclitaxel alone (p=0.031), and PFS and OS analyses are expected in April 2026; a Phase 2 CRC monotherapy study showed a 5% ORR, 68% DCR, median PFS of 3.9 months, and median OS of 10.2 months. CTX-471, a CD137 agonist, has shown monotherapy responses in post-PD-1/PD-L1 patients, with a Phase 2 basket study in NCAM+ tumors planned for mid-2026. CTX-8371 (PD-1 x PD-L1) is in Phase 1 with cohort expansions underway in NSCLC and TNBC, while CTX-10726 (PD-1 x VEGF-A) received FDA IND clearance and entered Phase 1 in early 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.8M$42M$43M+ $83M short-term inv.$12M-$45M operating cash flowreport ↗
2023-FY$0$38M$24M+ $128M short-term inv.$11M-$41M operating cash flowreport ↗
2022-FY—$30M$35M+ $152M short-term inv.$9.8M-$34M operating cash flowreport ↗
2021-FY—$20M$145M+ $0 short-term inv.$21M-$20M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 5 purchases ($103K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Lerner Neil · Chief Accounting OfficerOpen-market purchase10,000$0.59$6KForm 4
2026-10-01Lerner Neil · Chief Accounting OfficerOpen-market purchase20,000$0.92$18KForm 4
2026-09-24Lerner Neil · Chief Accounting OfficerOpen-market purchase2,500$1.14$3KForm 4
2026-04-29Anderman Jonathan · General CounselOpen-market purchase25,000$1.89$47KForm 4
2026-04-29Lerner Neil · Chief Accounting OfficerOpen-market purchase15,000$1.89$28KForm 4
2026-04-29Lerner Neil · Chief Accounting OfficerAward / grant15,000$1.89$28KForm 4
2026-04-29Anderman Jonathan · General CounselAward / grant25,000$1.89$47KForm 4
2026-02-08Schuetz Thomas J. · director, CHIEF EXECUTIVE OFFICERTax withholding36,687$6.52$239KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 200 reporting institutions held 173.2M shares ($917.7M, 96.2% of shares outstanding).

#InstitutionSharesValue
1TANG CAPITAL MANAGEMENT LLC16,790,809$88.8M
2ORBIMED ADVISORS LLC15,219,994$80.5M
3SUVRETTA CAPITAL MANAGEMENT, LLC14,307,379$75.7M
4Vivo Capital, LLC9,545,466$50.5M
5BlackRock, Inc.9,506,080$50.3M
6ADAGE CAPITAL PARTNERS GP, L.L.C.8,486,500$44.9M
7ENAVATE SCIENCES GP, LLC7,788,150$41.2M
8BVF INC/IL7,764,842$41.1M
9STATE STREET CORP6,694,976$35.4M
10VANGUARD CAPITAL MANAGEMENT LLC6,037,175$31.9M
11RTW INVESTMENTS, LP4,186,599$22.1M
12DEERFIELD MANAGEMENT COMPANY, L.P.3,606,000$19.1M
13GEODE CAPITAL MANAGEMENT, LLC3,565,770$18.9M
14Rock Springs Capital Management LP3,305,308$17.5M
15Logos Global Management LP3,150,000$16.7M